Vieta E, et al. - This randomized, double-blind, exploratory study was performed to investigate the effects of vortioxetine vs escitalopram on outcomes of cognition, functioning and mood symptoms in depressed patients with inadequate response to current antidepressant treatment. The outcomes confirmed vortioxetine in doses of 10 to 20 mg/day as an efficacious and well-tolerated antidepressant switch treatment, although this explorative study did not meet primary endpoints. Across cognition endpoints, the overall direction of numerical effect sizes supported previous findings that in major depressive disorder (MDD), vortioxetine specifically benefited cognitive function.